Publicaciones en colaboración con investigadores/as de Corporació Sanitària Parc Taulí (21)

2022

  1. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466

  2. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

2021

  1. Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)

    Critical Care

  2. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

    Critical Care, Vol. 25, Núm. 1

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Home Mechanical Ventilation

    Open Respiratory Archives, Vol. 2, Núm. 2, pp. 67-88

2019

  1. Prevalence and outcome of diuretic resistance in heart failure

    Internal and Emergency Medicine, Vol. 14, Núm. 4, pp. 529-537

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  3. Influence of renal dysfunction phenotype on mortality in decompensated heart failure with preserved and mid-range ejection fraction

    International Journal of Cardiology, Vol. 243, pp. 332-339

2016

  1. Differences between familial and sporadic early spondyloarthritis: Results from the ESPERANZA cohort

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 4, pp. 575-580

  2. Long-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis

    PLoS ONE, Vol. 11, Núm. 8

2015

  1. In response: Genomic profile of breast cancer

    Expert Review of Pharmacoeconomics and Outcomes Research

2014

  1. Genomic profile of breast cancer: Cost-effectiveness analysis from the Spanish National Healthcare System perspective

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, Núm. 6, pp. 889-899

2012

  1. Recognition of anxiety disorders by the general practitioner: Results from the DASMAP Study

    General Hospital Psychiatry, Vol. 34, Núm. 3, pp. 227-233

2010

  1. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain

    Clinical and Translational Oncology, Vol. 12, Núm. 10, pp. 692-700

  2. Factor structure, internal consistency and construct validity of the Sheehan Disability Scale in a Spanish primary care sample

    Journal of Evaluation in Clinical Practice, Vol. 16, Núm. 5, pp. 895-901

2009

  1. Cooperación entre atención primaria y servicios de salud mental

    Atencion Primaria, Vol. 41, Núm. 3, pp. 131-140